City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.
July 17, 2017 | City of Hope
Cancer care has come a long way. Surgery, chemotherapy and radiation have traditionally been the three pillars of cancer care, and they are still important treatments. But in recent years, newer “targeted therapies” have come on the scene.
January 30, 2015 | Tami Dennis
If you haven’t heard the term “precision medicine,” you will. If you don’t have an opinion about access to it, you will. Precision medicine is expected to grow by leaps and bounds with the recently announced Precision Medicine Initiative.
January 1, 2015 | Tami Dennis
Every year, researchers make gains in the understanding of cancer, and physicians make gains in the treatment of cancer. As a result, every year, more cancer patients survive their disease. In 2015, cancer research will move forward in ways both high-profile and little-heralded.
December 30, 2014 | Tami Dennis
City of Hope's Jae Kim offers his perspective on expected esophageal cancer advances for 2015. Think “precision.” Doctors can now prescribe specific drugs that focus specifically on cancer cells, avoiding the healthy cells that need to be preserved.
December 20, 2014 | Hiu Chung So
The protein HER2 is most commonly associated with breast cancer, but it also plays a role in several other cancers — including esophageal cancer. Using this knowledge and the drug trastuzumab (Herceptin), which targets HER2, City of Hope researchers are conducting clinical trials with the hope of improving survival and quality of life for this hard-to-treat disease.
May 31, 2014 | Hiu Chung So
For women with ovarian cancer, the results of recent study could mean new hope for future treatments. The findings, reported at the American Society of Clinical Oncology's annual meeting, found that a combination of two experimental drugs, olaparib and cediranib, significantly lengthened the duration of progression-free survival compared to olaparib alone and standard chemotherapy.
February 7, 2014 | Kim Proescholdt
Multiple myeloma, a cancer of the blood plasma cells, is the second most common hematological malignancy in the U.S. (after non-Hodgkin lymphoma), and accounts for 1 percent of all cancers. It is generally thought to be incurable but highly treatable.
March 16, 2013 | Hiu Chung So
Targeted drugs are often touted as the holy grail of cancer therapy because they're able to hone in and kill cancer cells while leaving normal cells unscathed. Or that’s how they're supposed to work. Studies published earlier this month found that two targeted therapies did not benefit head and neck cancer patients, but the results provide direction for further research.